Market Research Reports and Industry Reports

Suda Ltd - Product Pipeline Review - 2015



 Global Markets Direct’s, ‘Suda Ltd - Product Pipeline Review - 2015’, provides an overview of the Suda Ltd’s pharmaceutical research and development focus.
 This report provides comprehensive information on the current therapeutic developmental pipeline of Suda Ltd’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 - The report provides brief overview of Suda Ltd including business description, key information and facts, and its locations and subsidiaries
 - The report reviews current pipeline of Suda Ltd’s human therapeutic division and enlists all their major and minor projects
 - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
 - Special feature on out-licensed and partnered product portfolio
 - The report summarizes all the dormant and discontinued pipeline projects
 - Latest company statement
 - Latest news and deals relating to the Suda Ltd’s pipeline products
 Reasons to buy

 - Evaluate Suda Ltd’s strategic position with total access to detailed information on its product pipeline
 - Assess the growth potential of Suda Ltd in its therapy areas of focus
 - Identify new drug targets and therapeutic classes in the Suda Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 - Develop strategic initiatives by understanding the focus areas of Suda Ltd and exploit collaboration and partnership opportunities
 - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Suda Ltd
 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 - Explore the dormant and discontinued projects of Suda Ltd and identify potential opportunities in those areas
 - Avoid Intellectual Property Rights related issues

Suda Ltd Snapshot 5
 Suda Ltd Overview 5
 Key Information 5
 Key Facts 5
 Suda Ltd - Research and Development Overview 6
 Key Therapeutic Areas 6
 Suda Ltd - Pipeline Review 8
 Pipeline Products by Stage of Development 8
 Pipeline Products - Monotherapy 9
 Suda Ltd - Pipeline Products Glance 10
 Suda Ltd - Clinical Stage Pipeline Products 10
 Phase II Products/Combination Treatment Modalities 10
 Phase I Products/Combination Treatment Modalities 11
 Suda Ltd - Unknown Stage Pipeline Products 12
 Unknown Products/Combination Treatment Modalities 12
 Suda Ltd - Drug Profiles 13
 sumatriptan succinate 13
 Product Description 13
 Mechanism of Action 13
 R&D Progress 13
 SUD-003 15
 Product Description 15
 Mechanism of Action 15
 R&D Progress 15
 SUD-004 16
 Product Description 16
 Mechanism of Action 16
 R&D Progress 16
 midazolam hydrochloride 17
 Product Description 17
 Mechanism of Action 17
 R&D Progress 17
 ondansetron hydrochloride 18
 Product Description 18
 Mechanism of Action 18
 R&D Progress 18
 Suda Ltd - Pipeline Analysis 20
 Suda Ltd - Pipeline Products by Target 20
 Suda Ltd - Pipeline Products by Route of Administration 21
 Suda Ltd - Pipeline Products by Molecule Type 22
 Suda Ltd - Pipeline Products by Mechanism of Action 23
 Suda Ltd - Recent Pipeline Updates 24
 Suda Ltd - Dormant Projects 26
 Suda Ltd - Discontinued Pipeline Products 27
 Discontinued Pipeline Product Profiles 27
 ondansetron hydrochloride 27
 ropinirole hydrochloride 27
 Suda Ltd - Locations And Subsidiaries 28
 Head Office 28
 Appendix 29
 Methodology 29
 Coverage 29
 Secondary Research 29
 Primary Research 29
 Expert Panel Validation 29
 Contact Us 29
 Disclaimer 30

List Of Tables

Suda Ltd, Key Information 5
 Suda Ltd, Key Facts 5
 Suda Ltd - Pipeline by Indication, 2015 7
 Suda Ltd - Pipeline by Stage of Development, 2015 8
 Suda Ltd - Monotherapy Products in Pipeline, 2015 9
 Suda Ltd - Phase II, 2015 10
 Suda Ltd - Phase I, 2015 11
 Suda Ltd - Unknown, 2015 12
 Suda Ltd - Pipeline by Target, 2015 20
 Suda Ltd - Pipeline by Route of Administration, 2015 21
 Suda Ltd - Pipeline by Molecule Type, 2015 22
 Suda Ltd - Pipeline Products by Mechanism of Action, 2015 23
 Suda Ltd - Recent Pipeline Updates, 2015 24
 Suda Ltd - Dormant Developmental Projects,2015 26
 Suda Ltd - Discontinued Pipeline Products, 2015 27

List Of Figures

Suda Ltd - Pipeline by Top 10 Indication, 2015 7
 Suda Ltd - Pipeline by Stage of Development, 2015 8
 Suda Ltd - Monotherapy Products in Pipeline, 2015 9
 Suda Ltd - Pipeline by Top 10 Target, 2015 20
 Suda Ltd - Pipeline by Top 10 Route of Administration, 2015 21
 Suda Ltd - Pipeline by Top 10 Molecule Type, 2015 22
 Suda Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015 23

Sudarshan Chemical Industries Ltd (SUDARSCHEM) - Financial and Strategic SWOT Analysis Review

Sudarshan Chemical Industries Ltd (SUDARSCHEM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125View Report

The Future of Sudan Automobile Markets to 2023- Trends, Drivers and Supply, Demand Outlook of Sudan Passenger Cars and Commercial Vehicles

Sudan Passenger cars and commercial vehicles outlook report provides detailed research and outlook of automobile sector in Sudan. Current market conditions, consumer preferences and key strategies of leading players in

USD 1249View Report

Sudan Telecommunications Strategic Analysis and Outlook to 2025- Analysis of Sudan Mobile, Fixed Telephone and Broadband Markets

Sudan Telecom outlook report is a comprehensive analytical research on the Sudans cellular, fixed telephone and fixed broadband segments. Through detailed analysis of the current market conditions and industry

USD 1350View Report

SFK Construction Holdings Ltd - Company Capsule

SynopsisTimetrics SFK Construction Holdings Ltd - Company Capsule contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products

USD 99View Report

UroGen Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

UroGen Pharmaceuticals Ltd (UroGen Pharma), formerly TheraCoat Ltd is a biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The companys pipeline products comprise drug candidates for various forms of

USD 250View Report

XuanZhu Pharma Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

XuanZhu Pharma Co Ltd (XuanZhu), a subsidiary of Sihuan Pharmaceutical Holdings Group Ltd is a healthcare company that research, develops, manufactures and sales drugs. The companys products include anti-infective drugs

USD 250View Report

Fill The Form For Sample Request
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


Discount on PDF and Enterprise Wide Licence reports
  • PDF    $ 1500
  • Site Licence    $ 3000
  • Enterprise Wide Licence    $ 4500
$ 1500

Reports Details

Published Date : Oct 2015
No. of Pages :30
Country :Global
Category :Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE


We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube